Medical News: No Cardiovascular Class Effect with Thiazolidinediones - in Endocrinology, Diabetes from MedPage Today
Links shared publicly online about this topic.
- 1,812total visits
Medical News: No Cardiovascular Class Effect with Thiazolidinediones - in Endocrinology, Diabetes from MedPage Today
Pioglitazone (Actos) carries less cardiovascular risk than its thiazolidinedione cousin rosiglitazone (Avandia), researchers affirmed in a population-based study.
View full resource at medpagetoday.com
Tags: Endocrinology, Diabetes, Diabetes Type 2 Medication, Diabetes Medication, Avandia, Avandamet, Avandaryl, Actos
Most Recently Shared on August 19, 2009 at 2:42 pm By:
No Cardiovascular Class Effect with Thiazolidinediones (CME/CE, with audio) http://ow.ly/15LBWm
Advertisement
